Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Cornea ; 40(11): 1502-1504, 2021 Nov 01.
Article in English | MEDLINE | ID: covidwho-2063050

ABSTRACT

ABSTRACT: The coronavirus disease 2019 global pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several ophthalmic manifestations have been reported to be associated with SARS-CoV-2 infection, including conjunctivitis, acute sixth nerve palsy, and multiple cranial neuropathies. We present a unique case of unilateral phlyctenular keratoconjunctivitis in a 5-year-old boy in the setting of SARS-CoV-2 infection.


Subject(s)
COVID-19/diagnosis , Conjunctivitis, Viral/diagnosis , Eye Infections, Viral/diagnosis , Keratoconjunctivitis/diagnosis , SARS-CoV-2/pathogenicity , Administration, Oral , Anti-Bacterial Agents/administration & dosage , Ascorbic Acid/administration & dosage , Azithromycin/administration & dosage , COVID-19/drug therapy , COVID-19/virology , COVID-19 Nucleic Acid Testing , Child, Preschool , Conjunctivitis, Viral/drug therapy , Conjunctivitis, Viral/virology , Drug Therapy, Combination , Eye Infections, Viral/drug therapy , Eye Infections, Viral/virology , Fluorometholone/therapeutic use , Glucocorticoids/therapeutic use , Humans , Keratoconjunctivitis/drug therapy , Keratoconjunctivitis/virology , Male , Ophthalmic Solutions , Slit Lamp Microscopy , Tomography, Optical Coherence , Visual Acuity/physiology
3.
Cornea ; 41(2): 254-256, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1636854

ABSTRACT

ABSTRACT: As the understanding of COVID-19 infection becomes better, it is being recognized as a complex multisystem pathology rather than just affecting the lungs. Several ocular findings have been documented by researchers in individuals infected with COVID-19, and ocular symptoms may even be the first presenting feature of COVID-19 infection in 2.26% individuals. Several countries have started vaccination with inactivated or live vaccines to combat this pandemic, and varied side effects have been reported after vaccination. Few cases of herpes zoster have previously been reported in elderly patients with comorbidities after receiving COVID-19 vaccines. In this article, the authors described 2 interesting cases of herpes zoster ophthalmicus (HZO) after receiving a live COVID-19 vaccine. The first case was a 35-year-old immunocompetent man who developed HZO 3 days postvaccine. The second case was a 40-year-old immunocompetent man who developed HZO 28 days postvaccine. To the best of our knowledge, no literature to date has described HZO after live vaccine.


Subject(s)
COVID-19/prevention & control , Conjunctivitis, Viral/etiology , Herpes Zoster Ophthalmicus/etiology , Vaccination/adverse effects , Acyclovir/therapeutic use , Administration, Ophthalmic , Administration, Oral , Adult , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/drug therapy , Drug Therapy, Combination , Herpes Zoster Ophthalmicus/diagnosis , Herpes Zoster Ophthalmicus/drug therapy , Humans , Male , Moxifloxacin/therapeutic use , SARS-CoV-2/immunology , Valacyclovir/therapeutic use , Visual Acuity/physiology
4.
Ocul Immunol Inflamm ; 29(6): 1225-1233, 2021 Aug 18.
Article in English | MEDLINE | ID: covidwho-1467232

ABSTRACT

The novel pandemic coronavirus disease 2019 (COVID-19) leading to health and economic problems worldwide is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although COVID-19 mainly occurs as a lower respiratory tract infection, there is multiorgan involvement in infected patients. The disease is transmitted from person to person through air droplets or contact with contaminated surfaces. SARS-CoV-2 leads to this systemic involvement by attaching to angiotensin-converting enzyme 2 (ACE2) receptors located on several human cells. Since SARS-CoV-2 RNA has been found in tears of infected patients, ocular surface may allow the virus to transmit to nasopharynx via the nasolacrimal duct. This narrative review aims to sum up all segmental ocular complications, ocular adverse effects of COVID-19 treatment, and preventive measures suggested to minimize the SARS-CoV-2 transmission between patients and ophthalmologists by reviewing currently available literature.


Subject(s)
COVID-19/diagnosis , Eye Infections, Viral/diagnosis , SARS-CoV-2 , Tears/virology , COVID-19/prevention & control , COVID-19/virology , COVID-19 Nucleic Acid Testing , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/prevention & control , Conjunctivitis, Viral/virology , Encephalitis, Viral/diagnosis , Encephalitis, Viral/prevention & control , Encephalitis, Viral/virology , Eye Infections, Viral/prevention & control , Eye Infections, Viral/virology , Humans , Preventive Medicine/methods , Retinal Diseases/diagnosis , Retinal Diseases/prevention & control , Retinal Diseases/virology , SARS-CoV-2/pathogenicity
5.
Ocul Immunol Inflamm ; 29(4): 666-668, 2021 May 19.
Article in English | MEDLINE | ID: covidwho-1303841

ABSTRACT

Purpose: To evaluate and establishe the number of patients with ocular manifestations in the early phase of systemic COVID-19 infection.Methods: A cross-sectional study was performed in a COVID-19 referral center regarding ocular findings in patients with COVID-19 in the first few days of the disease. The patients were submitted to a clinical examination, an ophthalmic exam and a RT-PCR for SARS-COV-2.Results: Out of 1740 patients, we reported 108 patients with ocular manifestations. Forty-nine with markedly conjunctivitis had conjunctival swab positive for SARS-COV-2, four of them developed keratitis. There were mostly no evidence of retinopathy nor decrease in visual acuity. They had no marked clinical symptoms, which can contribute and demonstrate that the virus may cause ocular disease as an only finding or in the very early stage of the infection.Conclusion: Patients were in the first days of COVID-19 infection, presented ocular manifestations suggested to be related to the virus and need to be aware of the pathways of transmissions.


Subject(s)
COVID-19/complications , Conjunctiva/pathology , Conjunctivitis, Viral/diagnosis , Eye Infections, Viral/diagnosis , RNA, Viral/analysis , SARS-CoV-2/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Brazil/epidemiology , COVID-19/epidemiology , COVID-19/virology , Conjunctiva/virology , Conjunctivitis, Viral/etiology , Conjunctivitis, Viral/virology , Cross-Sectional Studies , Eye Infections, Viral/etiology , Eye Infections, Viral/virology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pandemics , Time Factors , Young Adult
6.
Ocul Immunol Inflamm ; 29(4): 652-655, 2021 May 19.
Article in English | MEDLINE | ID: covidwho-1216508

ABSTRACT

Purpose: To evaluate the presence of SARS-CoV-2 in conjunctival secretions of COVID-19 patients.Material and Methods: In this retrospective study, the records were examined of patients who were treated in the hospital with the diagnosis of COVID-19 between March-May 2020 and were referred to the eye clinic due to ocular symptoms. Conjunctival swabs from both confirmed and suspected COVID-19 cases during hospitalization were analyzed.Results: A total of 35 patients (22 suspected, 13 laboratory-confirmed COVID-19) were referred to the eye clinic. Conjunctival swab samples from 3 patients yielded positive PCR results. These three patients were being treated in the intensive care unit, and all were suspected COVID-19 patients.Conclusion: SARS-CoV-2 may be detected in patients with suspected COVID-19. Even with conjunctivitis findings, SARS-CoV-2 may not be detected in most conjunctiva swab samples of COVID-19 patients.


Subject(s)
COVID-19/virology , Conjunctiva/metabolism , Conjunctivitis, Viral/diagnosis , Eye Infections, Viral/diagnosis , Adult , Aged , COVID-19/metabolism , Conjunctiva/pathology , Conjunctiva/virology , Conjunctivitis, Viral/metabolism , Conjunctivitis, Viral/virology , Eye Infections, Viral/metabolism , Eye Infections, Viral/virology , Female , Humans , Male , Middle Aged , RNA, Viral/analysis , Retrospective Studies , SARS-CoV-2/genetics , Specimen Handling
7.
Eye Contact Lens ; 47(4): 168-173, 2021 Apr 01.
Article in English | MEDLINE | ID: covidwho-1140027

ABSTRACT

PURPOSE: To assess the effect of severe acute respiratory syndrome coronavirus-2 infection on the conjunctiva and tear film. METHODS: Thirty-eight patients with confirmed COVID-19 and 31 healthy controls were included in this prospective and observational study. Individuals with COVID-19 formed the patient group, and healthy individuals formed the control group. Conjunctival impression cytology (CIC), TBUT, Schirmer II test, and ocular surface disease index were evaluated in all participants. RESULTS: No significant difference was observed regarding the mean age and gender between the groups (P=0.786 and P=0.122, respectively). The mean TBUT and Schirmer II test results did not differ between the two groups (P=0.496 and P=0.447, respectively). The CIC results revealed decreased density and cell size of goblet cells and moderate to high enlargement, squamous changes, and increased nucleocytoplasmic ratio in nongoblet epithelial cells in the COVID-19 group compared with the control group. Based on the Nelson classification in CIC samples, 60.6% of the COVID-19 group and 19.4% of the control group had changes consistent with grade 2 or above. The presence of neutrophils in CIC was significantly higher in the COVID-19 group (P<0.001), whereas the presence of lymphocyte was similar between the two groups (P=0.247). CONCLUSION: This study revealed the pathological conjunctival alterations in patients with COVID-19 and demonstrated that pathological ocular surface alterations may present even at the beginning of COVID-19 without clinically significant ocular manifestation.


Subject(s)
COVID-19/diagnosis , Conjunctiva/pathology , Conjunctivitis, Viral/diagnosis , Dry Eye Syndromes/diagnosis , Eye Infections, Viral/diagnosis , SARS-CoV-2/isolation & purification , Tears/virology , Adult , COVID-19 Nucleic Acid Testing , Cell Count , Cell Size , Conjunctivitis, Viral/virology , Cross-Sectional Studies , Cytological Techniques , Dry Eye Syndromes/virology , Eye Infections, Viral/virology , Female , Goblet Cells/pathology , Humans , Lymphocytes/pathology , Male , Middle Aged , Neutrophils/pathology , Prospective Studies , SARS-CoV-2/genetics , Young Adult
8.
Indian J Ophthalmol ; 69(3): 691-694, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1089039

ABSTRACT

PURPOSE: The aim of this study was to determine the frequency and various types of ophthalmic manifestation of patients with COVID-19. METHODS: This is a prospective observational study conducted on patients with SARS-Co-V-2 infection, at a dedicated tertiary COVID-19 hospital in South India from April 1 to July 31, 2020. At the time of their admission to the COVID hospital, demographic data such as name, age, sex was recorded. A thorough history regarding the onset, duration, progression, nature of symptoms and its associated factors, medication history, treatment history were elicited and documented. Ocular examination was performed under torchlight by an ophthalmologist posted for COVID duty. Further investigations including imaging were sought for, depending on clinical indications. Serial follow-up examinations of all patients were carried out every 72 hours or when patients complained of any ocular symptoms whichever earlier, until discharge. All relevant data were compiled and statistically analyzed. RESULTS: A total of 2742 patients were examined. Of them, 1461 (53.28%) were males and 1281 (46.72%) were females. The mean age (±SD) was 39.46 ± 17.63 years. None of the patients in our study had any ocular symptoms or signs as the presenting complaint at the time of their admission. On subsequent follow-up, only 20 (0.72%) developed ocular manifestations, of which 19 (95%) had features suggestive of Bilateral viral conjunctivitis. However, 1 (5%) patient had orbital cellulitis secondary to pansinusitis. CONCLUSION: Ophthalmic manifestations in the clinical spectrum of COVID-19 infection are uncommon and unlikely to be the presenting clinical impression. However, it has broadened our view to a wider spectrum of COVID-19 presentations enhancing our clinical acumen for staunch detection of COVID-19 suspects in our daily practice, augmenting early diagnosis and management and also break the chain of transmission for the greater good of humanity.


Subject(s)
COVID-19/complications , Conjunctivitis, Viral/etiology , Eye Infections, Viral/etiology , Pandemics , SARS-CoV-2 , Adult , Aged , COVID-19/epidemiology , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/epidemiology , Eye Infections, Viral/diagnosis , Eye Infections, Viral/epidemiology , Female , Humans , India/epidemiology , Male , Middle Aged , Prospective Studies
9.
Eur J Ophthalmol ; 31(2): NP161-NP166, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-671272

ABSTRACT

INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus causing an ongoing pandemic in 2020. Although the symptomatic patients infected by SARS-CoV-2 generally show respiratory distress, atypical manifestations such as conjunctivitis are also observed. A series of cases are reported in which reverse transcriptase polymerase chain reaction (RT-PCR) testing on tears had demonstrated the presence of the virus. However, the transmission of the virus through ocular fluids remains unknown. CASE DESCRIPTION: In this case report, the development of conjunctivitis is presented as the sole symptom of a new coronavirus disease 2019 (COVID-19) in an emergency health care worker. The patient's first application was to the ophthalmology clinic due to redness, stinging, tearing, and photophobia for one day in the right eye. The patient had no symptoms of fever, cough, shortness of breath, or fatigue. Two days later, the RT-PCR test, blood analysis, and chest computed tomography (CT) were applied to the patient for being in contact with a COVID positive patient. Conjunctival swabs did not identify SARS-CoV-2 by RT-PCR. However, nasopharyngeal swab and blood test confirmed the diagnosis of COVID-19. Chest CT did not show pneumonia. CONCLUSION: This phenomenon shows that conjunctivitis may occur as a sole manifestation of COVID-19 which needs to be carefully evaluated by health care workers and eye care professionals during the pandemic.


Subject(s)
COVID-19/diagnosis , Conjunctivitis, Viral/diagnosis , Eye Infections, Viral/diagnosis , SARS-CoV-2/isolation & purification , Administration, Ophthalmic , Adult , Anti-Bacterial Agents/therapeutic use , COVID-19/drug therapy , COVID-19 Nucleic Acid Testing , Conjunctivitis, Viral/drug therapy , Eye Infections, Viral/drug therapy , Humans , Male , Moxifloxacin/therapeutic use , Nurses , Occupational Exposure , Ophthalmic Solutions , Pneumonia, Viral/diagnostic imaging , RNA, Viral/analysis , SARS-CoV-2/genetics , Tears/virology , Tomography, X-Ray Computed
10.
Cornea ; 40(3): 348-350, 2021 Mar 01.
Article in English | MEDLINE | ID: covidwho-1066452

ABSTRACT

PURPOSE: This study was designed to detect CoV-RNA in the tears of polymerase chain reaction (PCR)-confirmed SARS-CoV-2 positive patients. METHODS: We performed a prospective case series study of hospitalized patients who have been confirmed SARS-CoV-2 positive by oropharyngeal swab within the previous 5 days. Tear samples obtained with a laboratory capillary and oropharyngeal swabs were analyzed by real-time PCR using the Altona SARS-CoV-2 Assay or the Roche SARS-CoV-2 LightMix PCR, depending on the availability. Patient history was documented, and ophthalmoscopy was used to assess for ocular surface disease. RESULTS: Of all 18 patients recruited in April 2020, 5 suffered from respiratory failure and were submitted to an intensive care unit. None of our patients had signs of viral conjunctivitis although all patients in intensive care showed chemosis and conjunctival hyperemia because of third-spacing or fluid overload. The presence of coronavirus RNA was confirmed by PCR in 5 of 18 patients (28%) in tears and 72% for oropharyngeal swabs. CONCLUSIONS: Using a tear fluid sampling technique similar to oropharyngeal lavage presents a higher percentage of SARS-CoV-2 positive tears in contrast to earlier reports that used a conjunctival swab. This does not automatically indicate viral shedding in ocular tissue or contagiousness of tear fluid.


Subject(s)
COVID-19/diagnosis , Conjunctivitis, Viral/diagnosis , Eye Infections, Viral/diagnosis , Oropharynx/virology , SARS-CoV-2/isolation & purification , Tears/virology , Adult , Aged , Aged, 80 and over , COVID-19/virology , COVID-19 Nucleic Acid Testing , Conjunctivitis, Viral/virology , Eye Infections, Viral/virology , Female , Germany/epidemiology , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Prospective Studies , RNA, Viral/genetics , SARS-CoV-2/genetics
11.
Cornea ; 40(3): 383-386, 2021 Mar 01.
Article in English | MEDLINE | ID: covidwho-1066450

ABSTRACT

PURPOSE: To present a patient with bilateral conjunctivitis, testing positive for viral RNA of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both nasopharyngeal and conjunctival samples. METHODS: A 40-year-old man with bilateral acute conjunctivitis and suspicious signs of coronavirus disease 2019 (COVID-19) presented to the hospital. A detailed ophthalmic examination was performed. Samples obtained from conjunctival and nasopharyngeal swabs were tested by reverse transcription PCR (RT-PCR) for the detection of SARS-CoV-2 virus. Ocular findings and duration of the presence of viral RNA in the conjunctival specimens were evaluated at follow-up visits. RESULTS: Slit-lamp biomicroscopy revealed bilateral acute follicular conjunctivitis. The RT-PCR assay demonstrated the presence of viral RNA in the nasopharyngeal and conjunctival specimens at the initial visit and at the 4-day follow-up. Conjunctivitis findings were decreased after 4 days and recovered completely without any sequelae within10 days. The PCR results of both nasopharyngeal and conjunctiva specimens were negative for the viral RNA at 10 days. CONCLUSIONS: Bilateral conjunctivitis is rare in patients infected with COVID-19. Although it is difficult to detect viral RNA from conjunctival swabs, conjunctival secretions may be a source of contamination, and protective measures must be taken.


Subject(s)
COVID-19/virology , Conjunctiva/virology , Conjunctivitis, Viral/virology , Eye Infections, Viral/virology , Nasopharynx/virology , RNA, Viral/genetics , SARS-CoV-2/isolation & purification , Administration, Ophthalmic , Administration, Oral , Adult , Antirheumatic Agents/therapeutic use , Antiviral Agents/therapeutic use , COVID-19/diagnosis , COVID-19/drug therapy , COVID-19 Nucleic Acid Testing , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/drug therapy , Drug Therapy, Combination , Eye Infections, Viral/diagnosis , Eye Infections, Viral/drug therapy , Ganciclovir/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , Intraocular Pressure , Male , Pharmaceutic Aids/therapeutic use , Povidone/therapeutic use , SARS-CoV-2/genetics , Slit Lamp Microscopy , Visual Acuity
14.
Ocul Immunol Inflamm ; 28(6): 916-921, 2020 Aug 17.
Article in English | MEDLINE | ID: covidwho-737751

ABSTRACT

PURPOSES: To describe the prevalence of ocular features among COVID-19 patients and their relationship with clinical data, inflammatory markers and respiratory support therapy (including CPAP); to investigate SARS-CoV-2 in ocular secretions of symptomatic patients. METHODS: 172 COVID-19 patients were evaluated for presence of ocular manifestations. Clinical and laboratory data were also reviewed. Conjunctival swabs were analyzed for SARS-CoV-2 by RT-PCR. RESULTS: Forty-five patients (26.2%) reported ocular manifestations. Patients treated with CPAP were more likely to have ocular abnormalities (p <.01). The presence of ocular symptoms was not associated with more significant alterations on blood tests. Conjunctival swabs from patients with suspect conjunctivitis yielded negative results for SARS-CoV-2. CONCLUSIONS: Ocular features are not infrequent in COVID-19 patients, but the presence of SARS-CoV-2 in ocular secretions is low. Ocular manifestations in hospitalized COVID-19 patients can also be a consequence of respiratory support therapy. Prevention of possible transmission through ocular secretions is still recommended.


Subject(s)
Betacoronavirus/genetics , Conjunctiva/virology , Conjunctivitis, Viral/etiology , Coronavirus Infections/complications , Pandemics , Pneumonia, Viral/complications , RNA, Viral/analysis , COVID-19 , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/virology , Coronavirus Infections/epidemiology , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Pneumonia, Viral/epidemiology , SARS-CoV-2
15.
Graefes Arch Clin Exp Ophthalmol ; 258(11): 2501-2507, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-734094

ABSTRACT

PURPOSE: The purpose of this study was to evaluate the frequency and clinical presentation of conjunctivitis in hospitalized patients with COVID-19. METHODS: A cross-sectional study was conducted at the Hospital Clinico San Carlos of Madrid, Spain. A total of 301 subjects from the COVID admission unit with laboratory-confirmed SARS-CoV-2 infection were included. The presence and clinical characteristics of conjunctivitis were evaluated. Laboratory, radiological, and clinical results in patients with and without conjunctivitis stratified by sex were analyzed. RESULTS: Of the 301 subjects included, 180 patients (59.8%) were male and the median age was 72 years (IQ 59-82). Overall, 35 patients (11.6%) were diagnosed with acute conjunctivitis. We found no relationship between the COVID-19 severity score and the presence of conjunctivitis (P = 0.17). However, conjunctivitis was more frequent in males with moderate clinical severity and in women classified as clinically mild. The natural history of the disease seems to be a rapid self-limited conjunctivitis that improves without treatment and does not affect visual acuity nor associate short-term complications. CONCLUSIONS: Approximately, 1 out of 10 hospitalized non-critical COVID-19 patients presents conjunctivitis during the disease. Compared with other viral conjunctivitis, we found distinctive clinical findings that could guide defining and differentiating conjunctivitis in COVID-19 patients. TRIAL REGISTRATION NUMBER: 20/336_E_COVID.


Subject(s)
Betacoronavirus/isolation & purification , Conjunctivitis, Viral/epidemiology , Coronavirus Infections/epidemiology , Eye Infections, Viral/epidemiology , Pneumonia, Viral/epidemiology , Aged , Aged, 80 and over , COVID-19 , Conjunctivitis, Viral/diagnosis , Coronavirus Infections/diagnosis , Cross-Sectional Studies , Eye Infections, Viral/diagnosis , Female , Hospitalization , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Prevalence , Risk Factors , SARS-CoV-2 , Spain/epidemiology
16.
Invest Ophthalmol Vis Sci ; 61(10): 29, 2020 08 03.
Article in English | MEDLINE | ID: covidwho-717438

ABSTRACT

Purpose: This systematic review aimed to determine currently reported clinical and prodromal ocular symptoms in patients with coronavirus disease 2019 (COVID-19). Methods: An online article search was performed in PubMed and EMBASE. Altogether 15 studies (retrospective, prospective, or case studies) involving 1533 patients with COVID-19, reporting on ocular symptoms, and with outcome data available were identified. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines were followed. Study-specific estimates (incidence rates of ocular symptoms in patients with COVID-19) of cases were combined using one-group meta-analysis in a random-effects model. Results: Of all included studies, 11.2% (95% confidence interval, 5.5-16.9; 78/1526 cases) reported ocular symptoms. The most common ocular finding was conjunctivitis. Prodromal ocular symptoms occurred in 12.5% (13/104 cases) of patients with COVID-19. Positive real-time polymerase chain reaction results were obtained for 16.7% (10/60 cases) of conjunctival samples and 0% (0/17 cases) of tear samples. Twelve ocular conjunctival swab samples tested positive for SARS-CoV-2. Ten cases were from subjects showing ocular symptoms (16.7%, 10/60 cases), and the remaining two cases were from subjects without ocular manifestation (1.8%, 2/113 cases). Limitations included the short study period, small sample size, findings were limited to the Asian population, only seven articles included ophthalmologic examination details, and there is currently no consensus on COVID-19 management. Conclusions: Ocular symptoms may occur in the presymptomatic phase as a prodromal symptom (12.5%, 13/104 cases), suggesting the possibility of viral transmission from the conjunctiva.


Subject(s)
Conjunctivitis, Viral/epidemiology , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Prodromal Symptoms , Severe Acute Respiratory Syndrome/diagnosis , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques/methods , Conjunctivitis, Viral/diagnosis , Coronavirus Infections/diagnosis , DNA, Viral/analysis , Disease Progression , Female , Humans , Incidence , Male , Pandemics/prevention & control , Pneumonia, Viral/diagnosis , Prognosis , Real-Time Polymerase Chain Reaction/methods , Risk Assessment , Severe Acute Respiratory Syndrome/epidemiology
17.
Curr Opin Ophthalmol ; 31(5): 403-415, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-692439

ABSTRACT

PURPOSE OF REVIEW: To compile and report the ocular manifestations of coronavirus disease 2019 (COVID-19) infection and summarize the ocular side effects of investigational treatments of this disease. RECENT FINDINGS: Conjunctivitis is by far the most common ocular manifestation of COVID-19 with viral particles being isolated from tears/secretions of infected individuals. Multiple therapeutic options are being explored across a variety of medication classes with diverse ocular side effects. SUMMARY: Eye care professionals must exercise caution, as conjunctivitis may be the presenting or sole finding of an active COVID-19 infection. While no currently studied therapeutic agents have been found to reliably treat COVID-19, early vaccination trials are progressing and show promise. A video abstract is available for a more detailed summary. VIDEO ABSTRACT: http://links.lww.com/COOP/A36.


Subject(s)
Betacoronavirus/isolation & purification , Conjunctivitis, Viral/diagnosis , Coronavirus Infections/diagnosis , Drug-Related Side Effects and Adverse Reactions/etiology , Drugs, Investigational/adverse effects , Eye Diseases/chemically induced , Pneumonia, Viral/diagnosis , Tears/virology , COVID-19 , Conjunctivitis, Viral/drug therapy , Conjunctivitis, Viral/virology , Drug-Related Side Effects and Adverse Reactions/prevention & control , Eye Diseases/prevention & control , Humans , Pandemics , SARS-CoV-2
18.
Indian J Ophthalmol ; 68(8): 1546-1550, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-680101

ABSTRACT

PURPOSE: To find the clinical profile and prevalence of conjunctivitis and other ocular manifestations in mild COVID-19 positive patients in a nodal COVID-19 hospital. METHODS: A retrospective cross-sectional, single-center study conducted in 127 mild cases of COVID-19 positive patients admitted between 27th March and 19th April 2020 in a tertiary care COVID-19 hospital in north India. From the hospital records, demographic data is collected. Ocular history and ocular examinations were done by face-to-face survey during ward rounds. RESULTS: A total of 127 patients were included in the study with a median age of 38.8 years. Forty-eight (37.80%) patients had upper respiratory tract symptoms, 20 (15.75%) patients had systemic illness, 18 (14.17%) patients were using spectacles, and 50 (39.37%) patients had history of hand-eye contact. Out of 12 (9.45%) patients who had ocular complaints, 11 (8.66%) had ocular manifestation after admission. Among 11 patients, eight (6.29%) had conjunctival congestion. Three (3/8) patients had developed conjunctival congestion even before the manifestation of definite COVID-19 symptoms. Five patients (5/8) patients had no other associated ocular symptoms other than congestion. Six patients (6/8) had symptoms of upper respiratory tract infection. CONCLUSION: Mild conjunctivitis manifesting as conjunctival congestion is common and is one of the major ocular manifestations in COVID-19 positive patients even with milder disease.


Subject(s)
Betacoronavirus , Conjunctivitis, Viral/epidemiology , Coronavirus Infections/epidemiology , Eye Infections, Viral/epidemiology , Hospitals, Special/statistics & numerical data , Ophthalmology/statistics & numerical data , Pneumonia, Viral/epidemiology , Adolescent , Adult , Aged , COVID-19 , Child , Child, Preschool , Conjunctivitis, Viral/diagnosis , Coronavirus Infections/diagnosis , Cross-Sectional Studies , Eye Infections, Viral/diagnosis , Female , Humans , India/epidemiology , Male , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Prevalence , Retrospective Studies , SARS-CoV-2 , Tertiary Healthcare/statistics & numerical data
19.
Indian J Ophthalmol ; 68(8): 1675-1677, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-679354

ABSTRACT

A 65-year-old known diabetic, hypertensive, and asthmatic patient was admitted for suspected coronavirus disease 19 (COVID-19) infection following complaints of breathlessness. He tested positive for COVID-19 and was put on ventilation. He developed severe follicular conjunctivitis of the right eye while on a ventilator, which was treated conservatively. The resolution of ocular signs was noted over 2 weeks without any complications. This case highlights the timeline of events and discusses the late ophthalmic manifestations in patients with COVID-19 infection.


Subject(s)
Betacoronavirus , Conjunctivitis, Viral/diagnosis , Coronavirus Infections/diagnosis , Eye Infections, Viral/diagnosis , Pneumonia, Viral/diagnosis , Respiration, Artificial , Aged , Anti-Bacterial Agents/therapeutic use , COVID-19 , Conjunctivitis, Viral/drug therapy , Conjunctivitis, Viral/physiopathology , Coronavirus Infections/drug therapy , Coronavirus Infections/physiopathology , Eye Infections, Viral/drug therapy , Eye Infections, Viral/physiopathology , Follow-Up Studies , Humans , Lubricants/administration & dosage , Male , Moxifloxacin/therapeutic use , Ophthalmic Solutions , Pandemics , Pneumonia, Viral/drug therapy , Pneumonia, Viral/physiopathology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL